Scarica l'app Stockscreener
2.51
0.79%
-0.02
Dopo l'orario di chiusura:
2.55
0.04
+1.59%
Grace Therapeutics Inc Borsa (GRCE) Ultime notizie
Grace Therapeutics (GRCE) price target decreased by 47.83% to 6.12 - MSN
GRCE Q2 2026 Earnings: Narrower-Than-Expected Loss Drives EPS Beat, but Stock DeclinesPeak Earnings Alert - dars.gov.et
GRCE Stock On Track For Worst Week In 5.5 Years — What’s Driving The Selloff? - Stocktwits
Grace Therapeutics, Inc.(NasdaqCM:GRCE) added to Russell Microcap Value Benchmark Index - marketscreener.com
Grace Therapeutics, Inc.(NasdaqCM: GRCE) added to Russell 3000E Index - marketscreener.com
Grace Therapeutics, Inc.(NasdaqCM: GRCE) added to Russell Microcap Index - marketscreener.com
Grace Therapeutics, Inc.(NasdaqCM: GRCE) added to Russell 3000E Value Benchmark - marketscreener.com
GRCE Stock On Retail Watchlist: High-Stakes FDA Decision On Brain Bleed Drug Nears - Stocktwits
GRCE Should I Buy - Intellectia AI
Grace Therapeutics, Inc. Actuals & Estimates (NASDAQ:GRCE) - TradingView
GRCE Forecast — Price Target — Prediction for 2027 - TradingView
Quarterly GDP Featured in U.S. Next Week - Baystreet.ca
Quarterly GDP Featured In U.S. Next Week - Menafn
Craig-Hallum Maintains Grace Therapeutics(GRCE.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Grace Therapeutics (NASDAQ: GRCE) Reports FDA CRL, Schedules Meeting - Value The Markets
Grace Therapeutics (GRCE) Advances FDA Resubmission Efforts for GTx-104 - GuruFocus
Grace Therapeutics narrows FY26 net loss to $7.8 million - scanx.trade
Grace Therapeutics, Inc (GRCE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Grace Therapeutics, Inc (GRCE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Grace Therapeutics, Inc (GRCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Grace Therapeutics Reports 2026 Financial Results, Advances GTx-104 NDA Resubmission for aSAH Treatment After FDA CRL – STRIVE-ON Phase 3 Data Highlights and IP Expansion – Minichart - Minichart
Grace Therapeutics Updates GTx-104 Regulatory and Trial Progress - TipRanks
Grace Therapeutics (NASDAQ: GRCE) updates GTx-104 data, FDA CRL response and cash - Stock Titan
Grace Therapeut reports $7.8M net loss, $17.0M cash at FY2026 year-end - TradingView
GRCE: Net loss narrowed as GTx-104 advanced toward FDA resubmission, with strong trial results and IP gains - TradingView
Grace Therapeutics (NASDAQ: GRCE) narrows 2026 loss and details FDA path for GTx-104 - Stock Titan
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update - Moomoo
Grace: Fiscal Q4 Earnings Snapshot - marketscreener.com
Grace Therapeutics FY 2026: Net loss $(7.8)M, EPS $(0.47) — 10-K Summary - TradingView
GRCE: Net loss improved to $7.8M as R&D spending fell, but FDA CRL delays GTx-104 approval - TradingView
Grace Therapeutics (Nasdaq: GRCE) faces GTx-104 FDA CRL and writes down two pipeline drugs - Stock Titan
Grace Therapeutics, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026 - marketscreener.com
Grace Therapeutics, Inc (GRCE) Institutional Confidence - TradingKey
Grace Therapeutics reports 2026 fiscal results - grafa.com
Grace Therapeutics, Inc (GRCE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Grace Therapeutics, Inc (GRCE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Grace Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable - Stocktwits
GRCE Q4'25 Earnings: revenue estimate is 0 USD - TradingView
GRCE Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor ConfidenceReturn On Capital - newsline.com
GRCE Q1 2026 Earnings: EPS Beats Estimates by Wide Margin Amid No Reported RevenueEarnings Yield Spread - newsline.com
GRACE THERAPEUTICS INC (GRCE) Stock Chart - ChartMill
Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Shareholders to Connect - ACCESS Newswire
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Grace Therapeutics, Inc. (GRCE) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Grace Therapeutics, Inc. (GRCE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz - The National Law Review
Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-06-07 | Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:GRCE | Press Release - Stockhouse
We're Keeping An Eye On Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate - Sahm
Grace Therapeutics VP of Clinical Operations Departs Role - TipRanks
Grace Therapeutics (NASDAQ: GRCE) VP departs, enters 12‑month consulting agreement - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Investors to Connect - ACCESS Newswire
2026-06-05 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Investors to Connect | NDAQ:GRCE | Press Release - Stockhouse
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):